Abstract
This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Current Drug Safety
Title:A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Volume: 9 Issue: 3
Author(s): Akihiro Hirakawa, Kan Yonemori, Yachiyo Kuwatsuka, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Akinobu Hamada, Chikako Shimizu, Kenji Tamura, Akihiko Gemma and Yasuhiro Fujiwara
Affiliation:
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Abstract: This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Export Options
About this article
Cite this article as:
Hirakawa Akihiro, Yonemori Kan, Kuwatsuka Yachiyo, Kodaira Makoto, Yamamoto Harukaze, Yunokawa Mayu, Hamada Akinobu, Shimizu Chikako, Tamura Kenji, Gemma Akihiko and Fujiwara Yasuhiro, A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140601205940
DOI https://dx.doi.org/10.2174/1574886309666140601205940 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fabrication, Optimization and Characterization of Paclitaxel and Spirulina Loaded Nanoparticles for Enhanced Oral Bioavailability
Current Nanoscience The Emerging Role of the Histamine H4 Receptor in Anti-inflammatory Therapy
Current Topics in Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets Enlarging the NSAIDs Family: Ether, Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Novel Anti-Inflammatory and Analgesic Agents
Current Medicinal Chemistry Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews In Silico Assessment of ADME Properties: Advances in Caco-2 Cell Monolayer Permeability Modeling
Current Topics in Medicinal Chemistry CXCL3 is a Potential Target for Breast Cancer Metastasis
Current Cancer Drug Targets The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Chromosome 3 Translocations and Familial Renal Cell Cancer
Current Molecular Medicine A Review on Mechanisms of Anti Tumor Activity of Chalcones
Anti-Cancer Agents in Medicinal Chemistry Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?
Current Pharmaceutical Biotechnology Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells
Current Cancer Drug Targets DNA Interaction and Cytotoxic studies on Mono/Di-Oxo and Peroxo- Vanadium (V) complexes - A Review
Mini-Reviews in Medicinal Chemistry Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA